Vivus Trading Up 15.80% After CEO Appears On CNBC
October 26, 2009 10:56 AM
Vivus (VVUS) CEO Leland Wilson spoke with Mike Huckman on CNBC regarding Vivus and its prospects.
Vivus is seeking a corporate partner for its Qnexa drug. Vivus is also working on an erectile dysfunction drug.
Vivus reported on Saturday that there was significant weight loss in patients regardless of their BMI. In other words, the drug didn't work differently in people who weighed more.
Vivus is now trading up 15.79% to $10.63.







